In the News
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. FDA announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.
Hodgkin lymphoma is typically considered to be one of the most curable forms of cancer, but some with the disease relapse. For patients like this, a fully human monoclonal antibody called avelumab has shown promising results in a phase 1 clinical trial for safety and efficacy.
Alex F. Herrera, M.D., and a team of doctors examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose chemotherapy and underwent an autologous stem cell transplantation.
Everything changed when Hodgkin lymphoma patient Lowell Winer joined a phase 2 clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
Cancer researchers increasingly realize that drug combinations, as opposed to single drugs, may be the best treatment approach. If so, some are asking, why not entirely different treatment regimens to create the ultimate weapon against tumors? City of Hope researchers are addressing that possibility by combining two approaches at which they excel.